Other sets contain a mixture of predictive and diagnostic biomarker considerations (e.g., to distinguish benign from malignant soft tissue tumors, or identify the presence of an EGFR activating mutation in a poorly differentiated tumor with equivocal immunophenotype). This evidence concerns the gene EGFR and soft tissue neoplasm.